CD274 and cancer: Notably, while PD-L1 inhibition with nivolumab is recommended in adults with advanced cancers with a combined positive score ≥ 5 regardless of HP status, it has been reported that HP-positive patients had a higher risk of non-response to PD-L1 inhibition [23,47,48].